|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | CONSORT 2010说明与详述:报告平行对照随机临床试验指南的更新显示文摘大量证据显示随机对照临床试验(randomised controlled trial,RCT)的报告质量不理想。报告不透明,则读者既不能评判试验结果是否真实可靠,也不能从中提取可用于系统综述的信息。最近的方法学分析表明,报告不充分和设计不合理与对治疗效果产生评价偏倚有关。这种系统误差对RCT损害严重,而RCT正是以其能减少或避免偏倚而被视为评价干预措施的金标准。为了提高RCT的报告质量,一个由专家和编辑组成的工作组制定了临床试验报告的统一标准(Consolidated Standards of Reporting Trials,CONSORT)声明。CONSORT声明于1996年首次发表,并于2001年更新。声明由对照检查清单和流程图组成,供作者在报告RCT时使用。许多核心医学期刊和主要国际性编辑组织都已认可CONSORT声明。该声明促进了对RCT的严格评价和解释。2001年,在对CONSORT进行修订时,人们就已经清楚地认识到,解释和说明制定CONSORT声明的原理,有助于研究人员等撰写或评价临床试验报告。一篇CONSORT说明与详述文章于2001年同2001版CONSORT声明一起发表。2007年1月的专家会议之后,对CONSORT声明作了进一步修订并已发表,即'CONSORT2010声明'。这次更新对原版对照检查清单作了文字上的修改,使其更为明晰,并收入了与一些新近才认识到的主题相关的建议,如选择性报告结局产生的偏倚。说明与详述文件旨在加强人们对CONSORT声明的理解、应用和传播,这次也作了大量修订,对每一项新增或更新的清单条目的含义和增改理由进行了解释,提供了优秀的报告实例,还尽可能地提供了相关的经验性研究的参考文献。文中收入了若干流程图实例。'CONSORT2010声明'、其说明与详述文件,以及相关网站(www.consort-statement.org),对于改进随机临床试验报告必将有所裨益。 | David Moher Sally Hopewell Kenneth F Schulz Victor Montori Peter C Gφtzsche P J Devereaux Diana Elbourne Matthias Egger Douglas G Altman 周庆辉 卞兆祥 刘建平 | 2010 | 中西医结合学报2010，8，8： | 318 |
| 2 | Adverse events with bismuth salts for Helicobacter pylori eradication:Systematic review and meta-analysis显示文摘AIM: To assess the safety of bismuth used in Helico- bacter pylori (H pylori) eradication therapy regimens. METHODS: We conducted a systematic review and meta-analysis. MEDLINE and EMBASE were searched (up to October 2007) to identify randomised controlled tri- als comparing bismuth with placebo or no treatment, or bismuth salts in combination with antibiotics as part of eradication therapy with the same dose and duration of antibiotics alone or, in combination, with acid suppres- sion. Total numbers of adverse events were recorded. Data were pooled and expressed as relative risks with 95% confidence intervals (CI). RESULTS: We identified 35 randomised controlled tri- als containing 4763 patients. There were no serious adverse events occurring with bismuth therapy. There was no statistically significant difference detected in total adverse events with bismuth [relative risk (RR) = 1.01; 95% CI: 0.87-1.16], specific individual adverse events, with the exception of dark stools (RR = 5.06; 95% CI: 1.59-16.12), or adverse events leading to withdrawal of therapy (RR = 0.86; 95% CI: 0.54-1.37). CONCLUSION: Bismuth for the treatment of H pylori is safe and well-tolerated. The only adverse event oc- curring significantly more commonly was dark stools. | Alexander C Ford Peter Malfertheiner Monique Giguère José Santana Mostafizur Khan Paul Moayyedi | 2008 | World Journal of Gastroenterology2008，14，48： | 62 |
| 3 | 中国喉科医师应用反流体征评分量表的信度研究显示文摘目的评估中国喉科医师应用反流体征评分量表(reflux finding score,RFS)的信度。方法 2009-02-10~2009-04-30收集了在美国加州大学戴维斯分校医学中心耳鼻咽喉头颈外科嗓音和吞咽障碍诊疗中心就诊的喉疾病患者的喉镜图片50张。由中国医师李进让(作者本人)和RFS的设计者、美国喉科医师Peter C Belafsky分别分两次(间隔48h以上)对50张喉镜图片进行RFS双盲评分。之后应用统计学处理,进行组间和组内信度评估。结果中国喉科医师初次和第2次RFS评分的平均值分别为8.28±2.78和8.10±2.75,美国喉科医师的分别分8.20±2.77和7.84±3.13。中国喉科医师和美国喉科医师各次RFS评分的均值无统计学差异(P>0.05)。中国喉科医师和美国喉科医师2次RFS评分的相关系数分别为0.929和0.874。中国喉科医师和美国喉科医师第1次RFS评分的相关系数为0.703。我们把RFS≥7判定为异常,中国喉科医师和美国喉科医师的组内一致性分别为94%(κ=0.861,P<0.0001)和94%(κ=0.855,P<0.0001),组间一致性为88%(κ=0.663,P<0.0001)。结论中国喉科医师应用RFS对喉镜图片进行评分组内和组间有很好的一致性和重复性,说明中国喉科医师可以准确的应用RFS来进行咽喉反流性疾病患者的初筛。 | 李进让 Peter C Belafsky 张立红 | 2012 | 中国耳鼻咽喉头颈外科2012，19，7： | 49 |
| 4 | Influences of Ivabradine treatment on serum levels of cardiac biomarkers sST2, GDF-15, suPAR and H-FABP in patients with chronic heart failure显示文摘长期的心失败(CHF ) 代表住院和死亡的一个主要原因。最近的证据表演那新奇 biomarkers 象 tumorigenicity (sST2 ) 的可溶的抑制那样,生长区别 factor-15 (GDF-15 ) ,可溶的尿激 plasminogen 使活跃之物受体(suPAR ) 和心类型丰满的酸绑定蛋白质(H-FABP ) 被相关与煽动性并且在 CHF 病人的 ischemic 回答。在这研究,我们检验了禁止了 激活hyperpolarization 的周期的核苷酸门隧道的 Ivabradine 的效果( HCN 隧道,也叫的滑稽电流我 从而导致选择心率减小的 f ),和改进的心肌的氧在心脏的 biomarkers sST2 上供应, GDF-15 ,在在 Jena 的大学医院的 50 个 CHF 病人的 suPAR 和 H-FABP 。病人们基于 CHF 的病原学被划分成三个组:扩大心肌症(DCM, n=20 ) , ischemic 心肌症(ICM, n=20 ) 并且高血压的心肌症(HCM, n=10 ) 。病人是管理 Ivabradine (5 mg,为 3 个月的出价,和 7.5 mg 期望推进 3 个月) 。心血管的 biomarkers 的分析在基线以及在 3 月、 6 月的后续被执行。在 6 月的后续, GDF-15 层次显著地与基线层次(P=0.0215 ) 相比被减少,显示在心脏的改变的进步的减小。H-FABP 集中在与 ICM (1.89 对 3.24 g/mL ) 和 HCM 病人(1.89 对 3.80 g/mL ) 相比的 DCM 病人是显著地更低的,并且在 6 月的后续(P=0.0151 ) 上减少了。中部的层次仍然是的 suPAR 提高了,暗示主要进行中的煽动性的过程。是在 GDF-15 和 H-FABP 由重要减少证明层次,在室的改变的减小和无临床症状的局部缺血能被假定。然而,血液动力学的应力(sST2 ) 的标记和发炎(suPAR ) 没在 CHF 病人在 6 月 Ivabradine 治疗以后显示出变化或前进。进一步的研究是必要的验证这些新奇心血管的 biomarkers 的临床的适用性。 | Peter JIRAK Dzeneta FEJZIC Vera PAAR Bernhard WERNLY Rudin PISTULLI Ilonka ROHM Christian JUNG Uta C HOPPE P Christian SCHULZE Michael LICHTENAUER Atilla YILMAZ Daniel KRETZSCHMAR | 2018 | Acta Pharmacologica Sinica2018，39，7： | 31 |
| 5 | 穿支皮瓣在组织器官缺损修复和再造中的应用显示文摘目的介绍5种穿支皮瓣在乳房、舌等器官再造,肿瘤切除或外伤等缺损修复中的应用。方法2005年6月~2006年6月,应用游离或带蒂的穿支皮瓣修复组织缺损和器官再造31例。其中采用股前外侧穿支皮瓣(anterolateral thigh flap,ALT)修复头颈部恶性肿瘤16例,包括恶性黑色素瘤9例,鳞癌4例,基底细胞癌2例,恶性纤维组织细胞瘤1例;肿瘤累及舌并行3/4舌切除再造舌3例;最大供瓣范围为26cm×15cm。腹壁下动脉系统穿支皮瓣(deep inferior epigastric perforator flap,DIEP)乳房再造10例,游离横形腹直肌肌皮瓣(free transverse rectus abdominis myocutaneous flap,FTRAM)2例,其中9例为单侧,3例为双侧;择期再造9例,即期3例,即期再造者行保留皮肤的乳腺切除术。臀上动脉穿支皮瓣(superior gluteal artery perforator flap,SGAP)、臀下动脉穿支皮瓣(inferior gluteal artery perforator flap,IGAP)再造乳房各1例。胫后动脉比目鱼肌带蒂穿支皮瓣(posterior tibial artery perforator flap,PTA)15cm×5cm修复小腿中下段缺损6cm×4cm伴骨外露1例。供瓣区直接缝合27例,3例ALT皮瓣和1例PTA皮瓣应用刃厚皮片覆盖供瓣区。结果应用游离皮瓣30例,带蒂皮瓣1例。皮瓣完全坏死1例,为ALT皮瓣修复肿瘤切除后颈部缺损,吻合血管为旋股外侧动脉降支与甲状腺上动脉,术后6d行坏死皮瓣清除,应用右侧胸大肌肌瓣加游离植皮术修复创面。1例双侧DIEP者部分脂肪液化,2例FTRAM乳房再造者术后2周腹部疼痛。PTA带蒂皮瓣远端静脉回流障碍,皮瓣远端2cm×1cm坏死,经换药愈合。所有患者获随访3~6个月,余各皮瓣成活良好,质地柔软,供区无并发症,供区植皮均成活。结论尽管穿支皮瓣存在血管变异,对解剖及手术操作技术要求高等不足,但在修复重建外科中仍代表最重要的进步,能以最小的供瓣区代价达到最高效的修复再造。 | 姚刚 周芳 Peter C Neligan | 2007 | 中国修复重建外科杂志2007，21，6： | 25 |
| 6 | VEGF-D expression correlates with colorectal cancer aggressiveness and is downregulated by cetuximab显示文摘AIM:To gain mechanistic insights into the role played by epidermal growth factor receptor (EGFR) in the regulation of vascular endothelial growth factors (VEGFs) in colorectal cancer (CRC). METHODS:The impact of high-level expression of the growth factor receptors EGFR and VEGF receptor (VEGFR)3 and the VEGFR3 ligands VEGF-C and VEGF-D on disease progression and prognosis in human CRC was investigated in 108 patients using immunohistochemistry. Furthermore, the expression of the lymphangiogenic factors in response to the modulation of EGFR signalling by the EGFR-targeted monoclonal antibody cetuximab was investigated at the mRNA and protein level in human SW480 and SW620 CRC cell lines and a mouse xenograft model. RESULTS: Human CRC specimens and cell lines displayed EGFR, VEGF-C and VEGF-D expression with varying intensities. VEGF-C expression was associated with histological grade. Strong expression of VEGF-D was significantly associated with lymph node metastases and linked to a trend for decreased survival in lymph node-positive patients. EGFR blockade with cetuximab resulted in a significant decrease of VEGF-D expression in vitro and in vivo. CONCLUSION:In conclusion, the expression of VEGF-D in colorectal tumours is significantly associated with lymphatic involvement in CRC patients and such expression might be blocked effectively by cetuximab. | Markus Moehler Christian Frings Annett Mueller Ines Gockel Carl C Schimanski Stefan Biesterfeld Institute of Pathology Johannes Gutenberg University Mainz 55101 Germany Peter R Galle Martin H Holtmann | 2008 | World Journal of Gastroenterology2008，14，26： | 15 |
| 7 | miR-182参与调节胶质母细胞瘤的凋亡、生长和分化(英文)显示文摘Glioblastoma multiforme(GBM)is a lethal,therapy-resistant brain cancer consisting of numerous tumor cell subpopulations,including stem-like glioma-initiating cells(GICs),which contribute to tumor recurrence following initial response to therapy.Here,we identified miR-182 as a regulator of apoptosis,growth,and differentiation programs whose expression level is correlated with GBM patient survival.Repression of Bcl2-like12(Bcl2L12),c-Met,and hypoxia-inducible factor 2α(HIF2A)is of central importance to miR-182 anti-tumor activity,as it results in enhanced therapy susceptibility,decreased GIC sphere size,expansion,and stemness in vitro.To evaluate the tumor-suppressive function of miR-182 in vivo,we synthesized miR-182-based spherical nucleic acids(182-SNAs);i.e.,gold nanoparticles covalently functionalized with mature miR-182 duplexes.Intravenously administered 182-SNAs penetrated the bloodbrain/blood-tumor barriers(BBB/BTB)in orthotopic GBM xenografts and selectively disseminated throughout extravascular glioma parenchyma,causing reduced tumor burden and increased animal survival.Our results indicate that harnessing the anti-tumor activities of miR-182 via safe and robust delivery of 182-SNAs represents a novel strategy for therapeutic intervention in GBM. | Kouri FM Hurley LA Daniel WL Day ES Hua Y Hao L Peng CY Merkel TJ Queisser MA Ritner C Zhang H James CD Sznajder JI Chin L Giljohann DA Kessler JA Peter ME Mirkin CA Stegh AH | 2015 | 中华神经外科疾病研究杂志2015，14，2： | 14 |
| 8 | 七个发达国家卫生系统的领导与治理显示文摘本文运用结构式调查方法,探讨了澳大利亚、英国、德国、荷兰、挪威、瑞典和瑞士七个发达国家卫生系统的领导和治理情况。领导与治理模式包含三项基本职能:优先顺序设置、绩效监管和问责制。各国卫生系统的领导和治理方法存在着显著差异,零散并略显随意。虽然各国在卫生系统的总体目标上达成了共识,但设置优先顺序的途径各不相同。成本效益分析作为设置卫生系统运行优先顺序的一个主要方法被各国加以广泛运用,但并未发挥核心作用。各国虽然处于不同的发展阶段,但绩效监管却能广泛吸收有益意见。问责制特别是在最优方法的不确定性方面,各国之间的差异最大。大多数情况下,市场机制、选举程序、直接经济激励以及专业监督与控制等几种不同问责机制的组合可能更为合适。而且这些机制应与优先顺序设置和绩效监管协调一致。 | Peter C Smith Anders Anell Reinhard Busse Luca Crivelli Judith Healy Anne Karin Lindahl Gert Westert Tobechukwu Kene | 2012 | 中国卫生政策研究2012，5，11： | 13 |
| 9 | Role of inflammation and infection in the pathogenesis of human acute liver failure: clinical implications for monitoring and therapy显示文摘Acute liver failure is a rare and devastating clinical condition. At present, emergency liver transplantation is the only life-saving therapy in advanced cases, yet the feasibility of transplantation is affected by the presence of systemic inflammation, infection and resultant multiorgan failure. The importance of immune dysregulation and acquisition of infection in the pathogenesis of acute liver failure and its associated complications is now recognised. In this review we discuss current thinking regarding the role of infection and inflammation in the pathogenesis of and outcome in human acute liver failure, the implications for the management of such patients and suggest directions for future research. | Mhairi C Donnelly Peter C Hayes Kenneth J Simpson | 2016 | World Journal of Gastroenterology2016，22，26： | 13 |
| 10 | Abdominal applications of diffusion-weighted magnetic resonance imaging: Where do we stand?显示文摘Diffusion-weighted imaging (DWI) is one of the magnetic resonance imaging (MRI) sequences providing qualitative as well as quantitative information at a cellular level. It has been widely used for various applications in the central nervous system. Over the past decade, various extracranial applications of DWI have been increasingly explored, as it may detect changes even before signal alterations or morphological abnormalities become apparent on other pulse sequences. Initial results from abdominal MRI applications are promising, particularly in oncological settings and for the detection of abscesses. The purpose of this article is to describe the clinically relevant basic concepts of DWI, techniques to perform abdominal DWI, its analysis and applications in abdominal visceral MR imaging, in addition to a brief overview of whole body DWI MRI. | Ajaykumar C Morani Khaled M Elsayes Peter S Liu William J Weadock Janio Szklaruk Jonathan Russell Dillman Asra Khan Thomas L Chenevert Hero K Hussain | 2013 | World Journal of Radiology2013，5，3： | 12 |
| 11 | 加强流行病学中观察性研究报告质量(STROBE)声明:观察性研究报告规范显示文摘很多生物医学研究都是观察性的。但对这类研究的报告却通常不完整,从而限制了对其优缺点及普适性的评价。“加强流行病学中观察性研究报告质量(STROBE)”工作组针对一篇完整明确的观察性研究报告应包括的内容提供了一套建议。建议涵盖了流行病学研究的三种主要设计类型:队列设计、病例对照设计和横断面设计。2004年9月,我们召开了为期2天的研讨会,与会的方法学专家、研究人员和期刊编辑共同起草了一份观察性研究报告应纳入的条目清单草案。此后,又通过协调小组数次会议及与有关人员电子邮件讨论等对该草案进行了修改,纳入了经验性证据和方法学方面的意见。通过研讨会及之后反复的咨询和修订,我们制定出了一个包含22个条目的清单(STROBE声明),分为论文的题目、摘要、引言、方法、结果和讨论等部分。其中18个条目适用于所有三种主要的观察性研究设计,其余4个条目则专门用于队列、病例一对照或横断面设计。详细的解释和示范文件已另行发表,在《公共科学图书馆一医学》(PLoS Medicine)、《内科学年报》(Annalsof Internal Medicine)和《流行病学》(Epidemiology)的网站可以免费获得。我们希望STROBE声明能有助于改善观察性研究报告的质量。 | Erikvon Elm Douglas G Altman Matthias Egger Stuart J Pocock Peter C G tzsche Jan P Vandenbroucke 赵乐(译) 邹光勇(审) 杜怀东(审) | 2008 | 世界临床医学2008，2，1： | 12 |
| 12 | Human thrombin for the treatment of gastric and ectopic varices显示文摘AIM:To evaluate the efficacy of human thrombin in the treatment of bleeding gastric and ectopic varices.METHODS:Retrospective observational study in a Tertiary Referral Centre.Between January 1999-October 2005,we identified 37 patients who were endoscopically treated with human thrombin injection therapy for bleeding gastric and ectopic varices.Patient details including age,gender and aetiology of liver disease/segmental portal hypertension were documented.The thrombin was obtained from the Scottish National Blood Transfusion Service and prepared to give a solution of 250 IU/mL which was injected via a standard injection needle.All patient case notes were reviewed and the total dose of thrombin given along with the number of endoscopy sessions was recorded.Initial haemostasis rates,rebleeding rates and mortality were catalogued along with the incidence of any immediate complications which could be attributable to the thrombin therapy.The duration of follow up was also listed.The study was conducted according to the United Kingdom research ethics guidelines.RESULTS:Thirty-seven patients were included.33 patients(89%) had thrombin(250 U/mL) for gastric varices,2(5.4%) for duodenal varices,1 for rectal varices and 1 for gastric and rectal varices.(1) Gastric varices,an average of 15.2 mL of thrombin was used per patient.Re-bleeding occurred in 4 patients(10.8%),managed in 2 by a transjugular intrahepatic portosystemic shunt(TIPSS)(one unsuccessfully who died) and in other 2 by a distal splenorenal shunt;(2) Duodenal varices(or type 2 isolated gastric varices),an average of 12.5 mL was used per patient over 2-3 endoscopy sessions.Re-bleeding occurred in one patient,which was treated by TIPSS;and(3) Rectal varices,an average of 18.3 mL was used per patient over 3 endoscopy sessions.No re-bleeding occurred in this group.CONCLUSION:Human thrombin is a safe,easy to use and effective therapeutic option to control haemorrhage from gastric and ectopic varices. | Norma C McAvoy John N Plevris Peter C Hayes | 2012 | World Journal of Gastroenterology2012，18，41： | 11 |
| 13 | Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients显示文摘AIM:To investigate the efficacy and safety of capecitabine plus irinotecan±bevacizumab in advanced or metastatic colorectal cancer patients. METHODS:Forty six patients with previously untreated,locally-advanced or metastatic colorectal cancer(mCRC) were recruited between 2001-2006 in a prospective open-label phaseⅡtrial,in German community-based outpatient clinics.Patients received a standard capecitabine plus irinotecan(CAPIRI) or CAPIRI plus bevacizumab(CAPIRI-BEV) regimen every 3 wk. Dose reductions were mandatory from the first cycle in cases of>grade 2 toxicity.The treatment choice of bevacizumab was at the discretion of the physician.Theprimary endpoints were response and toxicity and secondary endpoints included progression-free survival and overall survival. RESULTS:In the CAPIRI group vs the CAPRI-Bev group there were more female than male patients(47% vs 24%) ,and more patients had colon as the primary tumor site(58.8%vs 48.2%) with fewer patients having sigmoid colon as primary tumor site(5.9%vs 20.7%) .Grade 3/4 toxicity was higher with CAPIRI than CAPIRI-Bev:82%vs 58.6%.Partial response rates were 29.4%and 34.5%,and tumor control rates were 70.6%and 75.9%,respectively.No complete responses were observed.The median progression-free survival was 11.4 mo and 12.8 mo for CAPIRI and CAPIRI-Bev,respectively.The median overall survival for CAPIRI was 15 mo(458 d) and for CAPIRI-Bev 24 mo(733 d) .These differences were not statistically different.In the CAPIRI-Bev,group,two patients underwent a full secondary tumor resection after treatment,whereas in the CAPIRI group no cases underwent this procedure. CONCLUSION:Both regimens were well tolerated and offered effective tumor growth control in this outpatient setting.Severe gastrointestinal toxicities and thromboembolic events were rare and if observed were never fatal. | Markus Moehler Martin F Sprinzl Murad Abdelfattah Carl C Schimanski Bernd Adami Werner Godderz Klaus Majer Dimitri Flieger Andreas Teufel Juergen Siebler Thomas Hoehler Peter R Galle Stephan Kanzler | 2009 | World Journal of Gastroenterology2009，15，4： | 10 |
| 14 | Inflammatory bowel disease serology in Asia and the West显示文摘AIM:To study serological antibodies in Caucasians and Asians,in health and inflammatory bowel disease(IBD),in Australia and Hong Kong(HK).METHODS:Anti-glycan antibodies[anti-chitobioside(ACCA),anti-laminaribioside(ALCA)],and anti-mannobioside(AMCA),anti-Saccharomyces cervisiae(gASCA);and atypical perinuclear anti-neutrophil cytoplasmic antibody(pANCA)were tested in IBD patients,their unaffected relatives,and healthy controls in Australia and HK(China).Antibody status(positive or negative)and titre was compared between subjects of different geography,ethnicity and disease state.RESULTS:Ninety subjects were evaluated:21 Crohn’s disease(CD),32 ulcerative colitis(UC),29 healthy controls,and 8 IBD patient relatives.Forty eight subjects were Australian(29 Caucasian and 19 ethnic Han Chinese)and 42 were from HK(all Han Chinese).Caucasian CD patients had a significantly higher antibody prevalence of gASCA(67%vs 3%,P<0.001),ALCA(44%vs 6%,P=0.005),and AMCA(67%vs 15%,P=0.002),whereas HK CD patients had a higher prevalence of only AMCA(58%vs 25%,P=0.035),when compared with UC and healthy subjects in both countries.Caucasian CD had significantly higher gASCA prevalence(67%vs 0%,P<0.001)and titre(median59 vs 9,P=0.002)than HK CD patients.Prevalence and titres of ALCA,ACCA and AMCA did not differ between CD in the two countries.Presence of at least one antibody was higher in Caucasian than HK CD patients(100%vs 58%,P=0.045).pANCA did not differ between countries or ethnicity.CONCLUSION:Serologic CD responses differ between HK Asian and Australian Caucasian patients.Different genetic,environmental or disease pathogenic factors may account for these differences. | Lani Prideaux Michael A Kamm Peter De Cruz Daniel R van Langenberg Siew C Ng Iris Dotan | 2013 | World Journal of Gastroenterology2013，19，37： | 10 |
| 15 | 吸烟肺癌患者口腔黏膜细胞全线粒体DNA获得性突变分析 吸烟/口腔黏膜获得性突变与康复预防显示文摘目的了解肺癌患者口腔黏膜mtDNA获得性突变情况,探讨肺癌外细胞的线粒体基因突变与肺癌的关系和作为对肺癌预测的生物学指标的可能性。方法利用时相温度梯度凝胶电泳法对12例肺癌患者(吸烟者10例,非吸烟者2例)口腔黏膜细胞及匹配的血液细胞线粒体DNA进行突变筛选,然后进行测序分析。结果在大部分吸烟患者中(8/9),发现口腔黏膜具有两个以上的获得性突变,而在两个非吸烟的患者仅发现1个突变。在11例(11/12,92%)患者中共发现有26个获得性突变,15个突变发生在高变的D环区(58%),11个在mRNA区(42%)。除303~309位点具有长度不稳定外,未见其他微卫星不稳定和5kb的大范围缺失突变。结论吸烟的肺癌患者口腔黏膜细胞线粒体DNA具有高发生频率的获得性突变。 | 刘玲玲 谭端军 赵玉生 施伟伟 Peter Shields Lee-Jun C Wong | 2003 | 中国临床康复2003，7，15： | 10 |
| 16 | Computed tomography scans of paranasal sinuses before functional endoscopic sinus surgery显示文摘This review aims to familiarize the radiologist with the common types of sinus surgery including their indications and techniques.We also illustrate how surgeons interpret 3D sinus anatomy when evaluating computed tomography(CT)studies.Preoperative evaluation by CT is mandatory for all patients undergoing functional endoscopic sinus surgery(FESS).In the past decade in particular,CT of the paranasal sinuses has become a roadmap for FESS.The radiologist's goal is to report on five key points:the extent of sinus opacification,opacification of sinus drainage pathways,anatomical variants,critical variants,and condition of surrounding soft tissues of the neck,brain and orbits.We present a systematic approach to the use of coronal,axial,and sagittal images in CT evaluation before FESS. | Emma C Cashman Peter J MacMahon David Smyth | 2011 | World Journal of Radiology2011，3，8： | 10 |
| 17 | Helicobacter pylori upregulates prion protein expression in gastric mucosa: A possible link to prion disease显示文摘AIM: Pathological prion protein (PrPSC) is responsible for the development of transmissible spongiform encephalopathies (TSE). While PrPc enters the organism via the oral route, less data is available to know about its uptake and the role of gastrointestinal inflammation on the expression of prion precursor PrPc, which is constitutively expressed in the gastric mucosa.METHODS: We studied PrPc expression in the gastric mucosa of 10 Helicobacter pylori-positive patients before and after successful H pylori eradication compared to non-infected controls using RT-PCR and Western blotting.The effect of central mediators of gastric inflammation,i.e., gastrin, prostaglandin E2 (PGE2), tumor necrosis factor alpha (TNF-α) and interleukin 1 beta (IL-1β) on PrPc expression was analyzed in gastric cell lines.RESULTS: PrPc expression was increased in H pyloriinfection compared with non-infected controls and decreased to normal after successful eradication. Gastrin,PGE2, and IL-1β dose-dependently upregulated PrPc in gastric cells, while TNF-α had no effect.CONCLUSION: H pylori infection leads to the upregulation of gastric PrPc expression. This can be linked to H pylori induced hypergastrinemia and increased mucosal PGE2 and IL-1β synthesis.H pylori creates a milieu for enhanced propagation of prions in the gastrointestinal tract. | Peter C Konturek Karolina Bazela Vitally Kukharskyy Michael Bauer Eckhart G Hahn Detlef Schuppan | 2005 | World Journal of Gastroenterology2005，11，48： | 9 |
| 18 | Molecular targets in the treatment of alcoholic hepatitis显示文摘Alcohol related costs to health and society are high. One of the most serious complications of alcohol misuse to the individual is the development of alcoholic hepatitis (AH), a clinical syndrome of jaundice and progressive inflammatory liver injury in patients with a history of recent heavy alcohol use. It has a poor outcome and few existing successful therapies. The use of glucocorticoids in patients with severe AH is still controversial and there remains a group of patients with glucocorticoid-resistant disease. However, as our understanding of the pathogenesis of the condition improves there are opportunities to develop new targeted therapies with specific actions to control liver inflammation without having a detrimental effect on the immune system as a whole. In this article we review the molecular mechanisms of AH concentrating on the activation of the innate and adaptive immune response. We consider existing treatments including glucocorticoids, anti-tumor necrosis factor therapy and pentoxifylline and their limitations. Using our knowledge of the disease pathogenesis we discuss possible novel therapeutic approaches. New targets include pro-inflammatory cytokines such as interleukin (IL)-17, chemokines and their receptors (for example IL-8, CXCL9 and CXCR3) and augmentation of anti-inflam- matory molecules such as IL-10 and IL-22. And there is also future potential to consider combination therapy to selectively modulate the immune response and gain control of disease. | Ashwin D Dhanda Richard WL Lee Peter L Collins C Anne McCune | 2012 | World Journal of Gastroenterology2012，18，39： | 9 |
| 19 | Chemokine receptor CXCR4-prognostic factor for gastrointestinal tumors显示文摘To review the implication of CXCR4 for gastrointestinal cancer, a 'Pubmed' analysis was performed in order to evaluate the relevance of CXCR4 and its ligands for gastrointestinal cancers. Search terms applied were 'cancer, malignoma, esophageal, gastric, colon, colorectal, hepatic, pancreatic, CXCR4, SDF-1α, and SDF-1b'. CXCR4 expression correlated with dissemination of diverse gastrointestinal malignomas. The CXCR4 ligand SDF-1α might act as 'chemorepellent' while SDF-1b might act as 'chemorepellent' for CTLs, inducing tumor rejection. The paracrine expression of SDF-1α was furthermore closely associated with neoangiogenesis. CXCR4 and its ligands influence the dissemination, immune rejection, and neoangiogenesis of human gastrointestinal cancers. Inhibition of CXCR4 might be an interesting therapeutic option. | Carl C Schimanski Peter R Galle Markus Moehler | 2008 | World Journal of Gastroenterology2008，14，30： | 7 |
| 20 | Association between calcium sensing receptor gene polymorphisms and chronic pancreatitis in a US population:Role of serine protease inhibitor Kazal 1type and alcohol显示文摘AIM: To test the hypothesis that calcium sensing receptor (CASR) polymorphisms are associated with chronic pancreatitis (CP), and to determine whether serine protease inhibitor Kazal 1type (SPINK1) N34S oralcohol are necessary co-factors in its etiology. METHODS: Initially, 115 subjects with pancreatitis and 66 controls were evaluated, of whom 57 patients and 21 controls were predetermined to carry the high-risk SPINK1 N34S polymorphism. We sequenced CASR gene exons 2, 3, 4, 5 and 7, areas containing the majority of reported polymorphisms and novel mutations. Based on the initial results, we added 223 patients and 239 controls to analyze three common nonsynonymous single nucleotide polymorphisms (SNPs) in exon 7 (A986S, R990G, and Q1011E). RESULTS: The CASR exon 7 R990G polymorphism was signifi cantly associated with CP (OR, 2.01; 95% CI, 1.12-3.59; P = 0.015). The association between CASR R990G and CP was stronger in subjects who reported moderate or heavy alcohol consumption (OR, 3.12; 95% CI, 1.14-9.13; P = 0.018). There was no association between the various CASR genotypes and SPINK1 N34S in pancreatitis. None of the novel CASR polymorphisms reported from Germany and India was detected. CONCLUSION: Our United States-based study confirmed an association of CASR and CP and for the first time demonstrated that CASR R990G is a signifi cant risk factor for CP. We also conclude that the risk of CP with CASR R990G is increased in subjects with moderate to heavy alcohol consumption. | Venkata Muddana Janette Lamb Julia B Greer Beth Elinoff Robert H Hawes Peter B Cotton Michelle A Anderson Randall E Brand Adam Slivka David C Whitcomb | 2008 | World Journal of Gastroenterology2008，14，28： | 7 |
您所在的机构暂未开通此部分的功能，请联系管理员